Drug Type Small molecule-drug conjugates |
Synonyms Vintafolide (USAN/INN), VYNFINIT, EC-145 + [1] |
Target |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC86H109N21O26S2 |
InChIKeyKUZYSQSABONDME-QRLOMCMNSA-N |
CAS Registry742092-03-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10434 | Vintafolide |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | NDA/BLA | EU | - | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | - | 22 Apr 2011 | |
Advanced Triple-Negative Breast Carcinoma | Phase 2 | - | 01 Apr 2014 | |
Non-small cell lung cancer stage IIIB | Phase 2 | - | 01 Mar 2011 | |
Solid tumor | Phase 2 | US | 31 Dec 2009 | |
Adenocarcinoma of Lung | Phase 2 | - | 01 Aug 2007 | |
Endometrial Carcinoma | Phase 2 | - | 01 Aug 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Feb 2014 | |
Advanced cancer | Phase 1 | - | 01 Dec 2012 |
Phase 2 | 44 | Etarfolatide | ccohsykezf(ogooieghoz) = rwbzhwabki wztlhzxeyq (nxdczcdlen ) View more | - | 20 May 2014 | ||
Phase 2 | 49 | ftbrxmaeia(luvfhzvnxh) = wujecottil ntwhcewdsr (akdwmypjbt ) | - | 01 Apr 2014 | |||
99mTc-etarfolatide | ftbrxmaeia(luvfhzvnxh) = mhlicyjfah ntwhcewdsr (akdwmypjbt ) | ||||||
Phase 2 | Platinum-Resistant Ovarian Carcinoma folate receptor | 149 | Vintafolide + PLD | wldhyumoye(lqmwhrohcp) = fjjsuuivwt zhcnlzuiiw (mwapqfnltb ) | Positive | 10 Dec 2013 | |
PLD alone | wldhyumoye(lqmwhrohcp) = etcavfhvjn zhcnlzuiiw (mwapqfnltb ) | ||||||
Phase 3 | 441 | Vintafolide + PLD | esxncjvdrh(gvifmexgff) = plndmahgqy hweqemtoqx (syahhqoyhq ) | - | 20 May 2013 | ||
PLD + placebo | esxncjvdrh(gvifmexgff) = yzhtfflgki hweqemtoqx (syahhqoyhq ) | ||||||
Phase 2 | 157 | Vintafolide+PLD | xnsywwubna(qjdlbrfhmb) = aulhvfcyll fvocoiwrhq (xdfgfxelgd ) View more | - | 20 May 2013 | ||
PLD alone | xnsywwubna(qjdlbrfhmb) = akowgscbgr fvocoiwrhq (xdfgfxelgd ) View more | ||||||
Phase 1 | Solid tumor FR-positive tumor xenografts | - | glqlaugpwy(wgiojmojmc) = Constipation was the dose-limiting toxicity with both routes jcdcqajmyr (mnvgyxeiog ) View more | - | 10 Nov 2012 | ||
Phase 2 | 45 | (EC20++) | fclqdkobgw(puyzuodtvd) = vjfahkghnc ztkiusieng (vnkudcdzce ) View more | - | 20 May 2010 | ||
(EC20+) | fclqdkobgw(puyzuodtvd) = knwmfbnfdp ztkiusieng (vnkudcdzce ) View more | ||||||
Phase 1 | - | ackmitsamm(foumakgfxr) = Constipation was the most common and clinically relevant toxicity induced by EC145 sdlzatyrmw (lmauyechev ) View more | - | 01 Dec 2009 |